You have probably heard about the weight-loss shots that have reshaped waistlines across the country. Most of the attention has gone to the number on the scale. A new animal study points to a different reason some patients may be benefiting.
Researchers at the Smidt Heart Institute at Cedars-Sinai, led by Mahmoud Elbatreek, tested low-dose semaglutide. That is the active ingredient in Novo Nordisk's Ozempic and Wegovy.
They gave the drug to rats and minipigs with a form of obesity-related heart failure. The work was published in the European Heart Journal in October 2026.
The animals' hearts became less stiff, less swollen and less scarred, even though the dose was too low to cause meaningful weight loss.
Also read: Eating breakfast could change how you handle stress, new study suggests
The study was in animals, not people. It cannot yet prove the same effect happens in human patients. But it adds to a run of findings suggesting GLP-1 drugs do something directly to the heart muscle.
What heart failure with preserved ejection fraction actually is
The condition the researchers studied is called heart failure with preserved ejection fraction. The heart still squeezes normally, but the muscle has grown too stiff to relax and fill properly between beats.
The lungs and legs can swell with fluid, and even simple tasks can leave patients breathless. More than half of the roughly 6.7 million US adults with heart failure have this type, and there is no cure.
The low dose kept weight the same but still eased the heart
The rats got a dose of semaglutide about ten times lower than the usual human weight-loss dose. Over 16 weeks, their body weight barely moved.
Also read: Viral breathing techniques can cut blood flow to your brain by nearly half
The pressure inside the heart's main pumping chamber, a direct marker of stiffness, fell by around 60 percent. The size of the individual heart muscle cells shrank by roughly 30 percent, and the scarred tissue inside the heart dropped sharply.
In minipigs that already had the disease, a weekly injection reversed the damage in a similar way. Fat deposits built up around the heart and liver cleared out, while the fat under the skin stayed the same.
The researchers argue the pattern points to direct effects on heart muscle cells and the fibroblasts that lay down scar tissue, rather than any benefit funneled through weight loss.
Why the dose question matters for patients
About 1 in 10 US adults currently take a GLP-1 drug for weight loss, according to a Gallup survey from June 2026. Nausea, vomiting and other gut side effects are a common reason people stop.
Also read: Doctors warn: These symptoms can easily be mistaken for heartburn
"This opens the door to potentially prescribing GLP-1s at low doses to achieve major cardiovascular protection while minimizing common side effects," said Traci Goodchild. She is a professor of cardiac surgery at Cedars-Sinai.
If a smaller dose can protect the heart on its own, more patients might stay on treatment long enough to benefit. The authors call this a mechanism, not a treatment plan. Human trials at low doses would need to follow before any doctor could prescribe one for heart failure.
Patients already on Ozempic or Wegovy should not change their dose on their own. Anyone with symptoms of heart failure, such as breathlessness, swelling in the legs or new fatigue, should talk to their doctor.
Also read: How daily blueberries could help a crucial type of early memory decline
Also read: Study suggests 8 hours a week could nake a difference for Parkinson’s
This article is made and published by Jesper Bengtson, who may have used AI in the preparation.